United States· US:46708-268_c884ffd4-3a40-48a1-99b6-73b1ef9324b4
Celecoxib
A medicinal product containing celecoxib, registered in United States by Alembic Pharmaceuticals Limited.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CELECOXIB
- Manufacturer
- Alembic Pharmaceuticals Limited
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 12
- ndc1146708-268-12
- ndc1146708-268-30
- ndc1146708-268-31
- ndc1146708-268-60
- ndc1146708-268-71
- ndc1146708-268-91
- ndc11467082681280 CAPSULE in 1 CARTON (46708-268-12)
- ndc11467082683030 CAPSULE in 1 BOTTLE (46708-268-30)
- ndc114670826831100 CAPSULE in 1 BOTTLE (46708-268-31)
- ndc11467082686060 CAPSULE in 1 BOTTLE (46708-268-60)
- ndc114670826871500 CAPSULE in 1 BOTTLE (46708-268-71)
- ndc1146708268911000 CAPSULE in 1 BOTTLE (46708-268-91)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Celecoxib in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaACLEXAKrka, d.d., Novo mesto, Novo mesto
- United KingdomCelebrex 100mg capsulesStephar (U.K.) Ltd
- CanadaAG-CELECOXIBANGITA PHARMA INC.
- FranceCELEBREX 100 mg, géluleVIATRIS UP
- BelgiumCelebrex 100 mgViatris Healthcare
- NetherlandsBixocel 100 mg, capsules, hardSynthon B.V.
- FinlandCelebraViatris Healthcare Limited
- SwitzerlandCelebrex
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Celebrex, Celecoxib Ratiopharm
- Belgium · Celebrex, Celecoxib Ab
- Bulgaria · Аклекса, Дефинакс
- Cyprus · Celebrex, Celecoxib Accord
- Czechia · Aclexa, Celebrex
- Germany · Celebrex, Celecaxiro
- Denmark · Celebra, Celecoxib Accord
- Estonia · Aclexa, Celebrex
- Spain · Artilog, Axatal
- Finland · Celebra, Celecoxib Krka
- France · Celebrex, Celecoxib Arrow Lab
- United Kingdom (Northern Ireland) · Celebrex, Celecoxib
- Greece · Celebrex
- Croatia · Aclexa, Celixib
- Hungary · Aclexa, Celebrex
- Ireland · Celebrex, Celecoxib Accord Healthcare Ireland
- Iceland · Celebra, Celecoxib Actavis
- Italy · Celartrox, Celebrex
- Lithuania · Aclexa, Celecoxib Accord
- Luxembourg · Celebrex, Celecoxib Eg
- Latvia · Celebrex, Celecoxib Inteli
- Malta · Aclexa, Celebrex
- Netherlands · Bixocel, Celebrex
- Norway · Celebra, Celecoxib Accord
- Poland · Aclexa, Celebrex
- Portugal · Celebrex, Celecoxib Alter
- Romania · Aclexa, Capsule Teva
- Sweden · Celebra, Celecoxib Accord
- Slovenia · Aclexa, Celebrex
- Slovakia · Aclexa, Celebrex
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bc344c53-ced0-42d8-aa7e-09936e6fa090 GET /v1/drugs/bc344c53-ced0-42d8-aa7e-09936e6fa090?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "100",
"substance": "CELECOXIB",
"productndc": "46708-268",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA204519",
"marketing_category": "ANDA"
}See everything about celecoxib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.